Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of TER-101 Topical Ointment to Assess Efficacy and Safety in Subjects With Mild to Moderate Atopic

This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis.

Inclusion Criteria:

• Adolescent or adult subject aged 12 - 65 years.
• Overall IGA score of 2 (mild) or 3 (moderate) at baseline on a 5-point IGA

Exclusion Criteria:

• AD with known hypersensitivity to excipients of TER-101 Ointment
• Subjects who are immunocompromised